natgillin/translations-raw huggingface dataset:
Det var en population af patienter, der i udtalt grad tidligere havde modtaget anden behandling, eftersom 46% tidligere havde modtaget BMT og 73% tidligere havde modtaget multi-stof kemoterapi. 
This was a population of heavily pretreated patients, as 46% had received prior BMT and 73% a prior multi-agent chemotherapy.
Progression blev defineret som enhver af følgende hændelser: progression til accelereret fase eller blastkrise, død, tab af CHR eller MCyR, eller patienter der ikke opnår CHR eller øget leukocyttal på trods af relevant terapeutisk behandling. 
Progression was defined as any of the following events: progression to accelerated phase or blast crisis, death, loss of CHR or MCyR, or in patients not achieving a CHR an increasing WBC despite appropriate therapeutic management.
Din læge vil fortælle dig om de mulige risici, der er forbundet med brug af Imatinib Teva under graviditeten. 
Your doctor will discuss with you the possible risks of taking Imatinib Teva during pregnancy.
• Smertefulde og/eller blæredannende hudlæsioner. 
• Painful and/or blistering skin lesions.
Imatinib Teva er et lægemiddel, der indeholder et aktivt stof kaldet imatinib. 
Imatinib Teva is a medicine containing an active substance called imatinib.
Patienterne blev fordelt i 3 hovedkategorier: Manglende hæmatologisk effekt (29%), manglende cytogenetisk effekt (35%) eller interferonintolerans (36%). 
The patients were distributed in three main categories: haematological failure (29%), cytogenetic failure (35%), or intolerance to interferon (36%).
Total bilirubin: = 1,5 ULN AST: >ULN (kan være normal or < ULN hvis total bilirubin er > ULN) 
Total bilirubin: = 1.5 ULN AST: >ULN (can be normal or < ULN if total bilirubin is > ULN)
En specialist i leversygdomme og i behandling af hepatitis B skal konsulteres, før behandling initieres hos patienter med positiv hepatitis B-serologi (herunder patienter med aktiv sygdom), og hvis patienten testes HBVpositiv under behandlingen. 
Experts in liver disease and in the treatment of hepatitis B should be consulted before treatment is initiated in patients with positive hepatitis B serology (including those with active disease) and for patients who test positive for HBV infection during treatment.
95 (37%) havde tidligere modtaget kemoterapi til behandling af enten accelereret fase eller blastkrise (”tidligere behandlede patienter”), hvorimod 165 (63%) ikke havde (”ubehandlede patienter”). 
95 (37%) had received prior chemotherapy for treatment of either accelerated phase or blast crisis (“pretreated patients”) whereas 165 (63%) had not (“untreated patients”).
Der er meget begrænset erfaring med Imatinib Teva ved denne indikation, og den er baseret på hæmatologiske og cytogenetiske responsrater. 
Experience with imatinib in this indication is very limited and is based on haematological and cytogenetic response rates.
Denne Ki værdi er langt højere end de forventede plasmaniveauer af imatinib hos patienter, og der forventes derfor ingen interaktion i forbindelse med samtidig administration af hverken 5-fluorouracil eller paclitaxel og imatinib. 
This Ki value is far higher than the expected plasma levels of imatinib in patients; consequently no interaction is expected upon co-administration of either 5-fluorouracil or paclitaxel and imatinib.
Imatinib interfererede ikke med biotransformationen af 5-fluorouracil, men hæmmede paclitaxelmetabolismen på grund af kompetitiv hæmning af CYP2C8 (Ki = 34,7 μm). 
Imatinib did not interfere with the biotransformation of 5-fluorouracil, but it inhibited paclitaxel metabolism as a result of competitive inhibition of CYP2C8 (Ki = 34.7 μM).
Ved 84 måneder var den estimerede samlede overlevelse 86,4% (83, 90) vs. 83,3% (80, 87) i henholdsvis de randomiserede imatinib- og IFN+Ara-C-grupper (p=0,073, log-rank test). 
At 84 months the estimated overall survival is 86.4% (83, 90) vs. 83.3% (80, 87) in the randomised imatinib and the IFN+Ara-C groups, respectively (p=0.073, log-rank test).
Der blev hos GIST patienter (studie B2222) observeret stigning i grad 3 eller 4 ALT (alaninaminotransferase) hos 6,8% og stigning i grad 3 eller 4 AST (aspartat aminotransferase) hos 4,8%. 
In GIST patients (study B2222), 6.8% of grade 3 or 4 ALT (alanine aminotransferase) elevations and 4.8% of grade 3 or 4 AST (aspartate aminotransferase) elevations were observed.
Major respons ved 12 måneder (%) 
Major response at 12 months (%)
Genoptag Imatinib Tevabehandlingen ved den tidligere dosis (dvs. før svære bivirkninger). 
Resume treatment with imatinib at previous dose (i.e. before severe adverse reaction).
Hvis niveauet af ADAMTS13antistoffer er forøget samtidig med lav ADAMTS13-aktivitet, må behandlingen med Imatinib Teva ikke genoptages. 
If anti-ADAMTS13-antibody is elevated in conjunction with low ADAMTS13 activity, treatment with Imatinib Teva should not be resumed.
a ANC < 0.5 x 10 
ANC < 0.5 x 10
ANC = fuldstændigt antal neutrofilocytter aopstået efter mindst 1 måneds behandling 
ANC = absolute neutrophil count a occurring at least after one month of treatment
Tabletterne er ca. 9 mm i diameter. 
The tablets are approximately 9 mm in diameter.
Patienterne havde i gennemsnit tidligere modtaget 14 måneders IFNbehandling med doser ≥2 x 106 IE/uge og var alle i sen kronisk fase med en gennemsnitlig tid siden diagnose på 32 måneder. 
Patients had received a median of 14 months of prior IFN therapy at doses ≥ 25 x 106 IU/week and were all in late chronic phase, with a median time from diagnosis of 32 months.
• Øjensmerter eller svækkelse af dit syn, blødning i øjnene. 
• Eye pain or deterioration in vision, bleeding in the eyes.
Effekten af imatinib-behandling på overlevelse i kronisk fase, nyligt diagnostiseret CML er blevet yderligere undersøgt i en retrospektiv analyse af ovenstående rapporterede imatinib-data med primærdata fra et andet fase III-studie hvor IFN+Ara-C (n=325) blev anvendt i et identisk behandlingsregime. 
The effect of imatinib treatment on survival in chronic phase, newly diagnosed CML has been further examined in a retrospective analysis of the above reported imatinib data with the primary data from another Phase III study using IFN+Ara-C (n=325) in an identical regimen.
Bivirkningsdatabasen for børn med Ph+ALL er meget begrænset, med der er ikke identificeret nye bivirkninger. 
The safety database for children with Ph+ALL is very limited though no new safety concerns have been identified.
Af 9 patienter med kronisk fase CML og tilgængelige cytogenetiske data opnåede henholdsvis 4 (44%) og 3 (33%) fuldstændigt og delvist cytogenetisk respons, med en McyR-rate på 77%. 
Out of 9 patients with chronic phase CML and cytogenetic data available, 4 (44%) and 3 (33%) achieved a complete and partial cytogenetic response, respectively, for a rate of MCyR of 77%.
Dette vil hjælpe med at beskytte dig mod maveproblemer, når du tager Imatinib Teva. 
This will help protect you from stomach problems when taking Imatinib Teva.
Grad 3 og 4 neutropeni sås hos henholdsvis 7,5% og 2,7% af patienterne og grad 3 trombocytopeni hos 0,7% af patienterne. 
Grade 3 and 4 neutropenia was seen in 7.5% and 2.7% of patients, respectively, and grade 3 thrombocytopenia in 0.7% of patients.
Hæmatologisk og cytogenetisk respons er bibeholdt i en periode varende fra henholdsvis 19-60 måneder (median 49 måneder) og 16-59 måneder (median 47 måneder). 
Haematological and cytogenetic responses have been sustained for a median of 49 months (range 19-60) and 47 months (range 16-59), respectively.
(3 timer, q 12 
(2 h, q 12
Yderligere seks patienter, behandlet med Imatinib Teva, er blevet beskrevet i 5 publicerede kasuistikker, alderen varierede fra 18 måneder til 49 år. 
A further 6 DFSP patients treated with imatinib were reported in 5 published case reports, their ages ranging from 18 months to 49 years.
Imatinibs effekt er baseret på generelle hæmatologiske og cytogene responsrater og progressionsfri overlevelse. 
The effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival.
Det er vigtigt, at du tager det så længe, lægen eller apotekspersonalet fortæller dig, at du skal. 
It is important that you do this as long as your doctor, pharmacist or nurse tells you to.
Samtidig anvendelse af rifampicin eller andre stærke CYP3A4induktorer og imatinib bør undgås. 
Concomitant use of rifampicin or other strong CYP3A4 inducers and imatinib should be avoided.
Major respons ved 24 måneder (%) 
Major response at 24 months (%)
Kontakt lægen, før du tager Imatinib Teva: hvis du har eller har haft lever-, nyre- eller hjerteproblemer. 
Talk to your doctor before taking Imatinib Teva: - if you have or have ever had a liver, kidney or heart problem.
Nogle lægemidler kan påvirke virkningen af Imatinib Teva, når de bruges samtidigt. 
Some medicines can interfere with the effect of Imatinib Teva when taken together.
Undersøgelse 0102 38 måneders data Myeloid blastkrise (n=260) 
Study 0102 38-month data Myeloid blast crisis (n=260)
I alt døde 71 (12,8%) og 85 (15,4%) patienter i henholdsvis imatinib- og IFN+Ara-C-grupperne. 
A total of 71 (12.8%) and 85 (15.4%) patients died in the imatinib and IFN+Ara-C groups, respectively.
Din læge kan beslutte at nedsætte eller øge dosis afhængig af, hvordan du responderer på behandlingen. 
Your doctor may prescribe a higher or lower dose depending on how you respond to the treatment.
I imatinib-armen blev patienterne behandlet med 400 mg daglig. 
In the imatinib arm, patients were treated with 400 mg daily.
Større cytogenetisk respons, hæmatologisk respons, molekulær respons (evaluering af minimal tilbageværende sygdom), tid til accelereret fase eller blastkrise samt overlevelse er de sekundære hovedeffektmål. 
Major cytogenetic response, haematological response, molecular response (evaluation of minimal residual disease), time to accelerated phase or blast crisis and survival are main secondary endpoints.
Diameteren af den filmovertrukne tablet er ca. 9 mm. 
The diameter of the film-coated tablet is approximately 9 mm.
På grund af kendt øget risiko for blødning i forbindelse med brug af imitanib (f.eks. hæmoragi) bør patienter med behov for antikoagulantia have heparin med lav molekylevægt eller standardheparin i stedet for coumarinderivater som warfarin. 
Because of known increased risks of bleeding in conjunction with the use of imatinib (e.g. haemorrhage), patients who require anticoagulation should receive low-molecular-weight or standard heparin, instead of coumarin derivatives such as warfarin.
Brug ikke lægemidlet efter den udløbsdato, der står på pakningen og blisterpakningen efter EXP. Udløbsdatoen er den sidste dag i den nævnte måned. 
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP.
Antallet af Imatinib Teva-kapsler afhænger af barnets tilstand, kropsvægt og højde. 
The amount of Imatinib Teva given will depend on your child's condition, body weight and height.
1800 mg til 3200 mg (så høj som 3200 mg daglig i 6 dage): Svaghed, myalgi, øget kreatininfosfokinase, øget bilirubin, gastrointestinale smerter. 
1800 mg to 3200 mg (as high as 3200 mg daily for 6 days): Weakness, myalgia, increased creatine phosphokinase, increased bilirubin, gastrointestinal pain.
Patienten bør testes for HBV-infektion før initiering af behandling med Imatinib Teva. 
Patients should be tested for HBV infection before initiating treatment with Imatinib Teva.
Af disse 11 patienter, blev 4 patienter optrappet til 800 mg daglig, hvoraf 2 af dem genopnåede cytogenetisk respons (1 delvist og 1 fuldstændigt, og den sidst nævnte opnåede også et molekulær respons), mens kun 1 af de 7 patienter, som ikke fik større dosis genopnåede et fuldstændigt cytogenetisk respons. 
Of these 11 patients, 4 patients escalated up to 800 mg daily, 2 of whom regained a cytogenetic response (1 partial and 1 complete, the latter also achieving a molecular response), while of the 7 patients who did not escalate the dose, only one regained a complete cytogenetic response.
Behandling med Imatinib Teva kan da genoptages ved reduceret daglig dosis. 
Treatment with imatinib may then be continued at a reduced daily dose.
Der var i samme publikation oplysning om længere varende opfølgningsdata fra 12 MDS/MPD-patienter med PDGFRomlejring (5 patienter fra studie B2225). 
The same publication reported long term follow-up data from 12 MDS/MPD patients with PDGFR gene rearrangements (5 patients from study B2225).
9 Muskuloskeletale smerter under behandling med imatinib eller efter seponering er blevet observeret efter markedsføring. 
9 Musculoskeletal pain during treatment with imatinib or after discontinuation has been observed in post-marketing.
Kapslen indeholder et hvidt til gulligt granuleret pulver. 
The content of the capsule is white to light yellow granulated powder.
Uomdannet imatinib er ansvarlig for ca. 25% af dosis (5% urin og 20% fæces), resten er metabolitter. 
Unchanged imatinib accounted for 25% of the dose (5% urine, 20% faeces), the remainder being metabolites.
Farmakoterapeutisk klassifikation: Protein-kinasehæmmer, ATC-kode: L01XE01 
Pharmacotherapeutic group: antineoplastic agents, protein kinase inhibitor, ATC code: L01XE01
21 patienter blev behandlet med 400 mg Imatinib Teva daglig, mens 3 patienter fik en lavere dosis. 
21 patients were treated with imatinib 400 mg daily, while the other 3 patients received lower doses.
Tabel 5 Kemoterapi-regime anvendt i kombination med imatinib i studie I2301 
Table 5 Chemotherapy regimen used in combination with imatinib in study I2301
Et hovedrespons kombinerer både fuldstændig og partiel respons: Fuldstændig (0% Ph+ metafaser), delvis (1-35%) 
A major response combines both complete and partial responses: complete (0% Ph+ metaphases), partial (1-35%)
Imatinib Tevas effekt på resultatet af knoglemarvstransplantation er ikke blevet bestemt. 
The effect of imatinib on the outcome of bone marrow transplantation has not been determined.
Ved brug af denne metode øgedes den estimerede kumulative responsfrekvens for førstevalgsbehandling med imatinib fra 12 måneders behandling til 84 måneders behandling som følgende: hhv. CHR fra 96,4% til 98,4% og CCyR fra 69,5% til 87,2%. 
Using this approach, the estimated cumulative response rates for first-line treatment with imatinib improved from 12 months of therapy to 84 months of therapy as follows: CHR from 96.4% to 98.4% and CCyR from 69.5% to 87.2%, respectively.
Hvis laboratorie- eller kliniske fund associeret med TMA forekommer hos en patient, som er i behandling med Imatinib Teva, skal behandlingen seponeres og der skal foretages en grundig undersøgelse for TMA, inklusiv ADAMTS13-aktivitet og anti-ADAMTS13-antistofbestemmelse. 
If laboratory or clinical findings associated with TMA occur in a patient receiving Imatinib Teva , treatment should be discontinued and thorough evaluation for TMA, including ADAMTS13 activity and antiADAMTS13-antibody determination, should be completed.
Du kan blive mere følsom overfor sollys, når du tager Imatinib Teva. 
You may become more sensitive to the sun while taking Imatinib Teva.
Hos voksne bør dosis reduceres fra 400 mg til 300 mg eller fra 600 mg til 400 mg, eller fra 800 mg til 600 mg, og hos børn fra 340 til 260 mg/m2/dag. 
In adults the dose should be reduced from 400 mg to 300 mg or from 600 mg to 400 mg or from 800 mg to 600 mg, and in children from 340 to 260 mg/m2/day.
Behandlingen kan enten gives til dit barn som én daglig dosis eller alternativt kan den daglige dosis deles og gives to gange (halvdelen om morgenen og den anden halvdel om aftenen). 
The treatment can either be given to your child as a once-daily dose or alternatively the daily dose can be split into two administrations (half in the morning and half in the evening).
Prilaz baruna Filipovica 25 10000 Zagreb Kroatien 
PLIVA Croatia Ltd. Prilaz baruna Filipovica 25 10000 Zagreb Croatia
• Brug ca. 50 ml til hver 100 mg tablet. 
• Use about 50 ml for each 100 mg tablet.
I IFN-armen blev patienterne behandlet med en måldosis IFN på 5 MIE/m2/dag subkutant i kombination med subkutant Ara-C 20 mg/m2/dag i 10 dage/måned. 
In the IFN arm, patients were treated with a target dose of IFN of 5 MIU/m2/day subcutaneously in combination with subcutaneous Ara-C 20 mg/m2/day for 10 days/month.
I denne retrospektive analyse af total overlevelse blev imatinibs overlegenhed vist i forhold til IFN+Ara-C (p<0,001); inden for 42 måneder var 47 (8,5%) imatinib-patienter og 63 (19,4%) IFN+Ara-C-patienter døde. 
In this retrospective analysis, the superiority of imatinib over IFN+Ara-C in overall survival was demonstrated (p<0.001); within 42 months, 47 (8.5%) imatinib patients and 63 (19.4%) IFN+Ara-C patients had died.
De mere hyppige bivirkninger var gastrointestinalblødning, konjunktivitis og stigning i transaminase eller bilirubin. 
The more frequent adverse reactions included gastrointestinal haemorrhages, conjunctivitis and elevation of transaminases or bilirubin.
Alle patienter blev efter induktion behandlet med imatinib og standard kemoterapi (se Tabel 3), og bcr-abl transkriptionerne var identiske i de to arme efter 8 ugers behandling. 
All patients received imatinib and consolidation chemotherapy (see Table 4) after induction and the levels of bcr-abl transcripts were identical in the two arms at 8 weeks.
In vitro resultater viste, at CYP3A4 var det primære CYP-enzym som katalysator af biotransformationen af imatinib. 
The in vitro results showed that CYP3A4 was the major human P450 enzyme catalysing the biotransformation of imatinib.
Undersøgelsens primære effektvariable var graden af det cytogenetiske hovedrespons (fuldstændigt plus partielt respons, 0-35% Ph+-metafaser i knoglemarven). 
The primary efficacy variable of the study was the rate of major cytogenetic response (complete plus partial response, 0 to 35% Ph+ metaphases in the bone marrow).
De voksne patienter, som er beskrevet i publiceret litteratur blev behandlet med enten 400 mg (fire tilfælde) eller 800 mg (et tilfælde) Imatinib Teva daglig. 
The adult patients reported in the published literature were treated with either 400 mg (4 cases) or 800 mg (1 case) imatinib daily.
• behandling af voksne patienter med inoperabel dermatofibrosarkom protuberans (DFSP) og voksne patienter med residiverende og/eller metastaserende DFSP som ikke er tilgængelig for kirurgi. 
• The treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.
400 mg imatinib to gange daglig havde en inhibitorisk effekt på CYP2D6-medieret metoprololmetabolisme, som gav en stigning af Cmax og AUC for metoprolol på cirka 23% (90%CI [1,16-1,30]). 
Imatinib at 400 mg twice daily had an inhibitory effect on CYP2D6-mediated metoprolol metabolism, with metoprolol Cmax and AUC being increased by approximately 23% (90%CI [1.16-1.30]).
Der er gennemført en større, åben, international, randomiseret, fase III multicenterundersøgelse med patienter med nydiagnosticeret Ph+ CML. 
One large, open-label, multicentre, international randomised phase III study has been conducted in patients with newly diagnosed Ph+ CML.
Imatinib Teva anvendes også til behandling af voksne med: - Myelodysplastiske/myeloproliferative sygdomme (MDS/MDP). 
Imatinib Teva is also a treatment for adults for: - Myelodysplastic/myeloproliferative diseases (MDS/MPD).
Der blev set PDGFR-omlejring hos 11 patienter, 9 af disse opnåede CHR og 1 PHR. 
In eleven patients PDGFR gene rearrangements was detected, 9 of them achieved a CHR and 1 PHR.
Årlige frekvenser af enhver type progression blev reduceret over tid med imatinib. 
The yearly rates of progression of any type for imatinib also decreased over time.
2 Hovedpine var hyppigst hos GIST-patienter. 
2 Headache was the most common in GIST patients.
Ved 7-års opfølgning var der 93 (16,8%) progressionshændelser i imatinib-armen: 37 (6,7%) omhandlede progression til accelereret fase/blastkrise, 31 (5,6%) tab af MCyR, 15 (2,7%) tab af CHR eller stigning i leukocytter, og 10 (1,8%) dødsfald ikke relateret til CML. 
With 7 years follow-up, there were 93 (16.8%) progression events in the imatinib arm: 37 (6.7%) involving progression to accelerated phase/blast crisis, 31 (5.6%) loss of MCyR, 15 (2.7%) loss of CHR or increase in WBC, and 10 (1.8%) CML unrelated deaths.
Den estimerede progressionsfri overlevelse efter 84 måneder var 81,2% i imatinib-armen og 60,6% i kontrolarmen (p<0,001). 
The estimated rate of progression-free survival at 84 months was 81.2% in the imatinib arm and 60.6% in the control arm (p<0.001).
Calciumhydrogenphosphat Crospovidon 
Calcium hydrogen phosphate Crospovidone
Patienter med nedsat nyrefunktion eller i dialyse bør gives den mindste anbefalede dosis på 400 mg dagligt som startdosis. 
Patients with renal dysfunction or on dialysis should be given the minimum recommended dose of 400 mg daily as starting dose.
Lymfoid blastkrise 
Lymphoid blast crisis
Frekvenskategorier er defineret ved brug af følgende konvention: Meget almindelig (≥1/10), almindelig (≥1/100 til <1/10), ikke almindelig (≥1/1.000 til <1/100), sjælden (≥1/10.000 til <1/1.000), 
(≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000),
Præbehandling med gentagne doser af rifampicin 600 mg efterfulgt af enkeltdosis imatinib 400 mg resulterede i fald i Cmax og AUC(0-∞) på mindst 54% og 74% af værdierne uden rifampicinbehandling. 
Pretreatment with multiple doses of rifampicin 600 mg followed by a single 400 mg dose of imatinib resulted in decrease in Cmax and AUC(0-∞) by at least 54% and 74%, of the respective values without rifampicin treatment.
Ialt 26 pædiatriske patienter i alderen <18 år med enten CML i kronisk fase (n=11) eller CML i blastkrise eller Ph+ akut leukæmi (n=15) blev inkluderet i en fase I undersøgelse med dosiseskalering. 
A total of 26 paediatric patients of age < 18 years with either chronic phase CML (n=11) or CML in blast crisis or Ph+ acute leukaemias (n=15) were enrolled in a dose-escalation phase I trial.
Hæmatologisk respons1 Fuldstændigt hæmatologisk respons (CHR) Intet tegn på leukæmi (NEL) 
Haematological response1 Complete haematological response (CHR) No evidence of leukaemia (NEL)
Undersøgelse 0110 37 måneders data Kronisk fase, IFN-svigt (n=532) 
Study 0110 37-month data Chronic phase, IFN failure (n=532)
Imatinib blev administreret periodisk i kohorte 1-5 med stigende varighed og tidligere start med imatinib fra kohorte til kohorte; kohorte 1 fik den mindst intensive imatinibbehandling og kohorte 5 den mest intensive (længste varighed i dage med kontinuerlig, daglig imatinibdosering i de første kemobehandlingsforløb). 
Imatinib was administered intermittently in cohorts 1-5, with increasing duration and earlier start of imatinib from cohort to cohort; cohort 1 receiving the lowest intensitiy and cohort 5 receiving the highest intensity of imatinib (longest duration in days with continuous daily imatinib dosing during the first chemotherapy treatment courses).
• Brug ca. 200 ml til hver 400 mg tablet. 
• Use about 200 ml for each 400 mg tablet.
Behandlingsvarighed: I kliniske undersøgelser fortsattes behandling med Imatinib indtil sygdomsprogression. 
Treatment duration: In clinical trials, treatment with imatinib was continued until disease progression.
Hvor estimeret 96% (93%) af patienterne med CCyR (PCyR) ved 12 måneder var fri for progression til accelereret fase/blastkrise ved 84 måneder, var kun 81% af patienterne uden CCyR ved 12 måneder fri for progression til fremskreden CML ved 84 måneder (p<0,001 samlet, p=0,25 mellem CCyR og PCyR). 
Whereas an estimated 96% (93%) of patients with CCyR (PCyR) at 12 months were free of progression to accelerated phase/blast crisis at 84 months, only 81% of patients without MCyR at 12 months were free of progression to advanced CML at 84 months (p<0.001 overall, p=0.25 between CCyR and PCyR).
• Voksne og pædiatriske patienter med Ph+ CML i kronisk fase efter manglende effekt af alfainterferonbehandling, eller i accelereret fase eller blastkrise. 
• Adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.
305 CZ-74770 Opava - Komárov Tjekkiet 
CZ-74770 Opava - Komárov